Natco Pharma Receives USFDA’s Final Approval For Generic Azacitidine

Natco Pharma on Tuesday has received final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Azacitidine for Injection, 100mg per vial, single-dose vial, a generic version of Vidaza by Celgene Corporation. 

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the US market in the near future. 

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of USD 188 million for the 12-month period ending April, 2017, based on industry sales data.

Natco Pharma Limited is a pharmaceutical company engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). 

For Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.